Medicare announces new payment rates for COVID-19 monoclonal antibody infusions
Effective immediately, Medicare will pay $750 to administer monoclonal antibodies to COVID-19 patients in their residence or temporary lodging and increase payment to administer them in most other care settings to $450 from $310 to better align payment with provider costs, the Centers for Medicare & Medicaid Services announced yesterday. CMS is updating its COVID-19 toolkits and coding resources to reflect the new payment rates.
Related News Articles
Headline
The Centers for Medicare & Medicaid Services July 2 issued a proposed rule that would increase Medicare hospital outpatient prospective payment system…
Headline
The Centers for Medicare & Medicaid Services July 1 launched the Medicare GLP-1 Bridge, a short-term demonstration program designed to provide eligible…
Headline
One year into the Rural Health Transformation Fund, what's working and what's next? In this conversation, Maya Sandalow, associate director of the Health…
Headline
The Department of Health and Human Services June 30 announced it will terminate emergency use authorization declarations for certain drugs and medical devices…
Headline
A blog by Noah Isserman, AHA director of health insurance and coverage policy, explains why a recent analysis by the Medicare Payment Advisory Commission…
Blog
Medicare Advantage now covers more than half of eligible Medicare beneficiaries, making its impact on hospitals, health systems and patients impossible to…